ResApp Health Limited
(ASX:RAP) has announced it has received its first institutional review board approval for its SMARTCOUGH-C study.
The study will evaluate the efficacy of the ResAppDx software application in the diagnosis of childhood pneumonia and other respiratory conditions using cough sounds.
Three US hospital sites will participate in the study, with the Cleveland Clinic the first to receive approval to commence enrolling patients.
ResApp’s ultimate goal is to enable an instant and accurate diagnostic test to be delivered via a smartphone, seeking to provide greater access to healthcare via the technology and reduce costs.
ResApp Health Limited posted a net loss of $3.2 million at 30 June 2016.
